Asarina Pharma AB (publ) Q3 Report 2021 released

Report this content

Asarina Pharma CEO Peter Nordkild: “While we made progress in several areas during Q3 2021, it was frustrating for us that our phase IIa study in Tourette Syndrome was delayed. We now expect our first patients to be included in the Study in December.”


  • Significant reduction in operating costs in Q3
  • Cash position on 30 September 2021 (SEK 23.5 million) still expected to cover the Tourette study



Following an administrative delay from Region Hovedstaden (the Capital Region of Denmark) we expect to receive final legal approval for our phase II proof of concept study in Tourette in Q4 2021, with the first patient to receive first dose of Sepranolone in December.

  • OCD

This quarter we have continued internal discussions on how best to finance a clinical study in OCD. This follows the granting of a US patent for Sepranolone for the treatment of Tourette, Obsessive-compulsive Disorder (OCD) and pathological gambling in June (valid until 2038).

To read the Report in full please visit:

For further information, please contact:

Peter Nordkild, CEO

Phone: +45 25 47 16 46


Jakob Dynnes Hansen, CFO

Phone: +45 5132 3698


Certified Adviser

Erik Penser Bank AB

Phone: +46 8-463 83 00



We are a Swedish biotech company developing Sepranolone for allopregnanolone-induced stress- and compulsivity-driven disorders. Our product pipeline is built on over 40 years of research into allopregnanolone-related neurological disorders. With our new family of GAMSA compounds (GABA-A Modulating Steroid Antagonists) we aim to deliver a new generation of safe, efficacious drugs for neurological conditions from Tourette syndrome to Obsessive compulsive disorder that still lack safe, efficacious pharmaceutical treatments.

The information above was provided by the CEO of Asarina Pharma AB (publ), for publication at 08.00 on November 25, 2021.